Open AccessBevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
Author(s) -
Lorenzo Antonuzzo,
Elisa Giommoni,
Davide Pastorelli,
Tiziana Pia Latiano,
Ida Pavese,
D. Azzarello,
Michele Aieta,
Ilaria Pastina,
Francesca Di Fabio,
A. Bertolini,
Domenico Corsi,
Selene Mogavero,
Valentina Angelini,
Mario Pazzagli,
Francesco Di Costanzo
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i23.7281
Subject(s) - medicine , bevacizumab , colorectal cancer , kras , adverse effect , population , clinical endpoint , progression free survival , gastroenterology , oxaliplatin , capecitabine , oncology , chemotherapy , cancer , surgery , randomized controlled trial , environmental health
To confirm the efficacy and safety of bevacizumab/XELOX combination for the treatment of locally advanced or metastatic colorectal cancer (CRC) in Italy.